POLYCYTHEMIA VERA
Clinical trials for POLYCYTHEMIA VERA explained in plain language.
Never miss a new study
Get alerted when new POLYCYTHEMIA VERA trials appear
Sign up with your email to follow new studies for POLYCYTHEMIA VERA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill for rare blood cancers shows promise in early trial
Disease control CompletedThis early-phase study tested a new drug called TQ05105 in 79 adults with certain blood cancers (myeloproliferative neoplasms). The main goals were to find the safest dose and understand side effects. The drug works by blocking a protein (JAK2) that can cause abnormal blood cell …
Matched conditions: POLYCYTHEMIA VERA
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Experimental combo targets Hard-to-Treat blood cancers
Disease control CompletedThis early-phase study tested a new drug called TGR-1202 combined with the standard drug ruxolitinib in 60 people with myelofibrosis or polycythemia vera. The goal was to see if the combination is safe and tolerable. Participants either had not responded well to ruxolitinib alone…
Matched conditions: POLYCYTHEMIA VERA
Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New pill could reduce Blood-Letting for rare blood cancer patients
Disease control CompletedThis phase 2 study tested an oral drug called bomedemstat in 20 adults with polycythemia vera, a rare blood cancer that causes too many red blood cells. The main goal was to see if the drug could safely lower red blood cell levels enough to avoid routine blood removal (phlebotomy…
Matched conditions: POLYCYTHEMIA VERA
Phase: PHASE2 • Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New Two-Step transplant shows promise for blood cancer patients
Disease control CompletedThis study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. First, patients received low-dose chemotherapy and radiation to prepare their bodies. Then, they got donor stem cells followed by drugs to prevent the donor cells from atta…
Matched conditions: POLYCYTHEMIA VERA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Drug dasatinib tested for rare blood cancers
Disease control CompletedThis study tested the drug dasatinib in 68 adults with several types of blood and bone marrow disorders, including certain leukemias, myelofibrosis, and mastocytosis. The goal was to see if dasatinib could help control the disease and to check its safety. Participants took dasati…
Matched conditions: POLYCYTHEMIA VERA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New Two-Step transplant shows promise for tough blood cancers
Disease control CompletedThis study tested a two-step stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor stem cells and immune cells to help destroy remaining cance…
Matched conditions: POLYCYTHEMIA VERA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New pill shows promise for rare blood cancer in early trial
Disease control CompletedThis early-phase trial tested a new drug called flonoltinib maleate in 31 people with myeloproliferative neoplasms (MPNs), a group of bone marrow cancers. The main goals were to check safety, find the right dose, and see how the body processes the drug. Researchers hope this drug…
Matched conditions: POLYCYTHEMIA VERA
Phase: PHASE1, PHASE2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug itacitinib tested for Hard-to-Treat myelofibrosis
Disease control CompletedThis phase 2 study tested the drug itacitinib in 4 people with myelofibrosis (a bone marrow disorder) who had already tried other treatments like ruxolitinib or fedratinib. The main goals were to check safety and find the right dose, and to see if it could shrink an enlarged sple…
Matched conditions: POLYCYTHEMIA VERA
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 26, 2026 13:11 UTC
-
Itch relief showdown: which drug stops water-induced agony?
Symptom relief CompletedThis study tested two oral medications, aprepitant and hydroxyzine, to see which better reduces severe itching triggered by water contact in people with myeloproliferative neoplasms (a type of blood cancer). 63 participants who had persistent itching rated 5 or higher on a 10-poi…
Matched conditions: POLYCYTHEMIA VERA
Phase: PHASE3 • Sponsor: University Hospital, Brest • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC